First US Food and Drug Administration (FDA) approved treatment of fatty liver with liver scarring (fibrosis)
posted: Jun. 10, 2024.
Rezdiffra has been US Food and Drug Administration (FDA) approved in 2024, for the use of patients with fatty liver and liver scarring (fibrosis). Please contact our office at 818 659 5887 for more information. We provide both a non invasive fatty liver scan to give you more liver health information and to determine if you are a candidate for this treatment option.